[Efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination therapy in the treatment of mild to moderate essential hypertension in China].
OBJECTIVE
To evaluate the efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination each with Metoprolol, Lisinopril or Hydrochlorothiazide in the 12 weeks treatment of mild to moderate essential hypertension in China.


METHODS
Multicenter, random samples, and open study have been processed.


RESULTS
(1)After 12 weeks associated combination treatment of anti-hypertension, the percentages of the persons who had attained the target were 80.2% of ITT group in Felodipine controlled release tablets associated combination with Hydrochlorothiazide, 74.1% of ITT group in with Metoprolol,and 80.5% of ITT group in with Lisinopril, respectively. (2)Mean reductions of systolic/diastolic blood pressure from baseline were 16.8/10.6 mm Hg in combination with Hydrochlorothiazide, 16.6/10.7 mm Hg in combination with Metoprolol,and 18.0/12.8 mm Hg in combination with Lisinopril each. There was no significant difference among these three groups (P>0.05). With the Felodipine controlled release tablets treatment alone, the mean reductions from baseline was 24.8/17.5 mm Hg. But in combination with Lisinopril, the blood pressure could lower more quickly, and then could reach the target more rapidly. (3)In the ITT group, the drug compliance with Felodipine controlled release tablets was 97.7%, with those in combination with Hydrochlorothiazide 89.8%, with those in combination with Metoprolol 100.0%, and with those in combination with Lisinopril 96.4%. The main adverse event related to Felodipine was headache, and to Lisinopril was cough.


CONCLUSIONS
Antihypertensive drug Felodipine controlled release tablets are good and effective. And Felodipine controlled release tablet associated combination each with Metoprolol, Lisinopril or Hydrochlorothiazide can make most patients reach the treatment target, with safety, good tolerance, and high compliance.
Chen
Yuan Yuan
YY
Department of Cardiology, Peking University People's Hospital, Beijing 100044, China.
Sun
Ning Ling
NL
Zhang
Wei Zhong
WZ
Wu
Hai Ying
HY
Zhang
Lin
L
Yu
Zhen Qiu
ZQ
Zhang
Fu Chun
FC
Xiang
Xiao Ping
XP
Liu
Hui Liang
HL
Shen
Fa Rong
FR
Tao
Jun
J
Zhao
Jiu An
JA
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002681:China; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015736:Felodipine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide; D006973:Hypertension / Q000188:drug therapy*; D017706:Lisinopril; D008297:Male; D008790:Metoprolol; D008875:Middle Aged; D010349:Patient Compliance
D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D006852:Hydrochlorothiazide; D017706:Lisinopril; D008790:Metoprolol; D015736:Felodipine